SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath® test that preferentially binds to cancer cells and causes them to fluoresce red under specific frequencies of light for detection in bodily fluids. The announcement marks the third year of collaboration.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
